You can buy or sell NTGN and other stocks, options, ETFs, and crypto commission-free!
Neon Therapeutics, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. Read More The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Renewable Energy Generation
Associated PressMay 8
Neon Therapeutics to Present at Bank of America Merrill Lynch 2019 Health Care Conference
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Press release content from Globe Newswire. The AP news staff was not involved in its creation. CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief Executive Officer of Neon, will present at the Bank of America Merrill Lynch 2019 Health Care Conference o...
-$0.73 per share
-$0.76 per share